This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

IntelGenx Technologies Gestione

Gestione criteri di controllo 2/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Dwight Gorham

Amministratore delegato

US$819.6k

Compenso totale

Percentuale dello stipendio del CEO	20.2%
Mandato del CEO	1.3yrs
Proprietà del CEO	n/a
Durata media del management	2.5yrs
Durata media del Consiglio di amministrazione	8.5yrs

Aggiornamenti recenti sulla gestione

Recent updates

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Dwight Gorham rispetto agli utili di IntelGenx Technologies?
Data	Compenso totale	Stipendio	Guadagni aziendali
Mar 31 2024	n/a	n/a	-US$11m
Dec 31 2023	US$820k	US$165k	-US$10m

Compensazione vs Mercato: La retribuzione totale di Dwight ($USD 819.56K ) è superiore alla media delle aziende di dimensioni simili nel mercato German ($USD 468.04K ).

Compensazione vs guadagni: Dati insufficienti per confrontare la retribuzione di Dwight con le performance aziendali.

AMMINISTRATORE DELEGATO

Dwight Gorham (66 yo)

1.3yrs

Mandato

US$819,564

Compensazione

Mr. Dwight Gorham serves as Chief Executive Officer of IntelGenx Technologies Corp. since April 13, 2023 and also serves as its Director since May 2024 and also Joined the company on April 13, 2023. He ser...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Dwight Gorham	CEO & Director	1.3yrs	US$819.56k	Nessun dato
André Godin	President & CFO	9yrs	US$422.32k	0.44% € 117.2k
Tommy Kenny	Senior VP & General Counsel	3.6yrs	US$176.92k	0.13% € 33.6k
Nadine Paiement	Vice-Chair of Scientific Advisory Board and VP of Research & Development - IntelGenx Corp	no data	US$163.33k	0.093% € 24.6k
Karen Kalayajian	Vice President of Finance & Administration	1.3yrs	Nessun dato	0.16% € 42.7k
Stephen Kilmer	Investor Relations Officer	no data	Nessun dato	Nessun dato
Ingrid Zerbe	Corporate Secretary	18.3yrs	Nessun dato	0.053% € 14.1k
Zenoz Pourhassan	VP of Quality Operations of Subsidiary	less than a year	Nessun dato	Nessun dato

2.5yrs

Durata media

53.5yo

Età media

Gestione esperta: Il team dirigenziale di 0IL è considerato esperto (durata media dell'incarico 2.5 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Dwight Gorham	CEO & Director	less than a year	US$819.56k	Nessun dato
Nadine Paiement	Vice-Chair of Scientific Advisory Board and VP of Research & Development - IntelGenx Corp	8.5yrs	US$163.33k	0.093% € 24.6k
Mark Nawacki	Independent Vice Chairman	8yrs	US$83.59k	0% € 0
Horst Zerbe	Chairman & Chairman of Scientific Advisory Board	18.3yrs	US$216.39k	0.0026% € 688.0
Serge Gauthier	Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato
Bernd Melchers	Independent Director	15.3yrs	US$83.59k	0.069% € 18.2k
Barry Greenberg	Member of Scientific Advisory Board	8.5yrs	Nessun dato	Nessun dato
Ludwig Aigner	Member of Scientific Advisory Board	8.5yrs	Nessun dato	Nessun dato
Monika Trzcinska	Independent Director	2.3yrs	US$75.57k	Nessun dato

8.5yrs

Durata media

61.5yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di 0IL sono considerati esperti (durata media dell'incarico 8.5 anni).

Analisi aziendale e situazione dei dati finanziari

Dati	Ultimo aggiornamento (ora UTC)
Analisi dell'azienda	2024/08/14 12:20
Prezzo dell'azione a fine giornata	2024/05/17 00:00
Guadagni	2024/03/31
Guadagni annuali	2023/12/31

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

Pacchetto	Dati	Tempistica	Esempio Fonte USA ^*
Dati finanziari della società	10 anni	Conto economico Rendiconto finanziario Bilancio	Modulo SEC 10-K Modulo SEC 10-Q
Stime di consenso degli analisti	+3 anni	Previsioni finanziarie Obiettivi di prezzo degli analisti	Rapporti di ricerca degli analisti Blue Matrix
Prezzi di mercato	30 anni	Prezzi delle azioni Dividendi, scissioni e azioni	Dati di mercato ICE Modulo SEC S-1
Proprietà	10 anni	Top azionisti Insider trading	Modulo 4 SEC Modulo 13D SEC
Gestione	10 anni	Team di leadership Consiglio di amministrazione	Modulo SEC 10-K Modulo SEC DEF 14A
Sviluppi principali	10 anni	Annunci aziendali	Modulo 8-K SEC

^* esempio per i titoli statunitensi, per quelli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più , cliccate qui.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.

Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su .

Fonti analitiche

IntelGenx Technologies Corp. è coperta da 8 analisti. 0 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

Analista	Istituzione
Benjamin Haynor	Aegis Capital Corporation
Douglas Loe	Echelon Wealth Partners Inc.
Christian Orquera	First Berlin Equity Research GmbH

This company listing is no longer active

IntelGenx Technologies Gestione

Gestione criteri di controllo 2/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

IntelGenx Technologies Corp. Announces Resignation of Dwight Gorham as Chief Executive Officer

IntelGenx Technologies Corp. Announces Board Resignations

IntelGenx Technologies Corp., Annual General Meeting, May 07, 2024

IntelGenx Technologies Corp. Announces Changes to its Board of Directors

Less than half of directors are independent

IntelGenx Technologies Corp. Announces the Resignation of J. Bernard (Bernie) Boudreau from the Board of Directors

Recent updates

IntelGenx Technologies Corp. Announces Resignation of Dwight Gorham as Chief Executive Officer

IntelGenx Technologies Corp. announced delayed 10-Q filing

ATAI Life Sciences AG entered into an agreement of purchase and sale to acquire the Assets of IntelGenx Technologies Corp. (OTCPK:IGXT).

ATAI Life Sciences AG entered into an agreement of purchase and sale to acquire the Assets of IntelGenx Technologies Corp. (OTCPK:IGXT).

IntelGenx Technologies Corp. Announces Board Resignations

First quarter 2024 earnings released: US$0.023 loss per share (vs US$0.017 loss in 1Q 2023)

Intelgenx Announces First Parkinson’S Disease Patients Dosed with Montelukast Versafilm® in Phase 2 ‘Montpark’ Clinical Trial

IntelGenx Corp. Updates Status of Buprenorphine Buccal Film ANDA

IntelGenx Technologies Corp., Annual General Meeting, May 07, 2024

New major risk - Financial position

Full year 2023 earnings released: US$0.057 loss per share (vs US$0.065 loss in FY 2022)

IntelGenx Technologies Corp. to Report Q4, 2023 Results on Mar 21, 2024

IntelGenx Technologies Corp. Announces Positive Results from Proof-Of-Concept Study to Assess the Palatability, Owner-Perceived Acceptability, and Ease of Repeated Administration of Intelgenx’s VetaFilm® Platform in Healthy Dogs and Cats

IntelGenx Technologies Corp. Announces Changes to its Board of Directors

IntelGenx Corp. Receives Approval to Conduct 'Montpark' Montelukast Versafilm Phase 2 Clinical Trial in Patients with Parkinson's Disease

Third quarter 2023 earnings released: US$0.016 loss per share (vs US$0.015 loss in 3Q 2022)

IntelGenx Technologies Corp. to Report Q3, 2023 Results on Nov 09, 2023

New minor risk - Shareholder dilution

Gensco® Pharma and Intelgenx Announces Rizafilm Commercialization Update in the United States

IntelGenx Corp. Provides Regulatory Update for Xiromed-Partnered Development Candidate, Buprenorphine Buccal Film

IntelGenx Technologies Corp. announced that it expects to receive CAD 9.43492 million in funding from ATAI Life Sciences AG

IntelGenx Technologies Corp. announced that it expects to receive CAD 8.42041 million in funding from ATAI Life Sciences AG

Intelgenx Technologies Corp. Completes Enrollment for `Buena' Montelukast Versafilm® Phase 2A Clinical Trial in Patients with Mild to Moderate Alzheimer's Disease

Second quarter 2023 earnings released: US$0.016 loss per share (vs US$0.017 loss in 2Q 2022)

IntelGenx Technologies Corp. to Report Q2, 2023 Results on Aug 14, 2023

Intelgenx Corp. Completes Enrollment for 'Buena' Montelukast Versafilm®? Phase 2A Clinical Trial in Patients with Mild to Moderate Alzheimer's Disease

Intelgenx Corp. Provides Update on Research Collaboration Evaluating Montelukast Versafilm for the Treatment of Parkinson's Disease

Less than half of directors are independent

IntelGenx Technologies Corp. Announces the Resignation of J. Bernard (Bernie) Boudreau from the Board of Directors

First quarter 2023 earnings released: US$0.017 loss per share (vs US$0.017 loss in 1Q 2022)

IntelGenx Technologies Corp. to Report Q1, 2023 Results on May 11, 2023

Full year 2022 earnings released: US$0.065 loss per share (vs US$0.068 loss in FY 2021)

IntelGenx Corp. Receives FDA Pdufa Date for Rizafilm®

Third quarter 2022 earnings released: US$0.015 loss per share (vs US$0.013 loss in 3Q 2021)

Third quarter 2022 earnings released: US$0.015 loss per share (vs US$0.013 loss in 3Q 2021)

IntelGenx Technologies Corp. to Report Q3, 2022 Results on Nov 10, 2022

IntelGenx Files Provisional U.S. Patent Application for Advanced Oral Film Formulation Improving Cannabinoid Onset of Action

IntelGenx Receives FDA GDUFA Date for Xiromed-Partnered Development Candidate, Buprenorphine Buccal Film

IntelGenx Corp. Submits Response to CRL from FDA for RIZAPORT VersaFilm

IntelGenx Announces Enrollment Reaches Halfway Mark in ‘BUENA’ Montelukast VersaFilm Phase 2a Clinical Trial in Patients with Mild to Moderate Alzheimer’s Disease

Second quarter 2022 earnings released: US$0.017 loss per share (vs US$0.017 loss in 2Q 2021)

IntelGenx Technologies Corp. to Report Q2, 2022 Results on Aug 11, 2022

Less than half of directors are independent

IntelGenx Technologies Corp. Elects Monika Trzcinska As Director

IntelGenx Technologies Corp. to Report Q1, 2022 Results on May 12, 2022

First Patient Dosed in IntelGenx Technologies Corp. Resumed ‘Buena’ Montelukast Versafilm Phase 2A Clinical Trial in Patients with Mild to Moderate Alzheimer’s Disease

Third quarter 2021 earnings released: US$0.013 loss per share (vs US$0.015 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.017 loss per share (vs US$0.015 loss in 2Q 2020)

IntelGenx Technologies Corp. announced that it has received $2.1 million in funding

First quarter 2021 earnings released: US$0.02 loss per share (vs US$0.024 loss in 1Q 2020)

Full year 2020 earnings released: US$0.065 loss per share (vs US$0.11 loss in FY 2019)

IntelGenx Technologies Corp. to Report Q4, 2020 Results on Mar 25, 2021

IntelGenx Technologies Corp., Annual General Meeting, May 11, 2021

IntelGenx Receives USPTO Notice of Allowance for its Novel DisinteQTM-Based Disintegrating THC Oral Film

IntelGenx Files Provisional U.S. Patent Application for Novel Vetafilmtm High Loading Oral Film Platform

New 90-day high: €0.30

Intelgenx Receives First Purchase Order for Cbd Filmstrips from Heritage Cannabis

New 90-day high: €0.22

Third quarter 2020 earnings released: US$0.015 loss per share

IntelGenx Corp. Announces Publication of a Study Evaluating Montelukast’s Effect on Neurological Aging

IntelGenx Technologies Corp. to Report Q3, 2020 Results on Nov 12, 2020

Heritage Cannabis Holdings Corp. Signs Letter of Intent with Intelgenx Technologies Corp. for Long-Term Cannabis Filmstrip Supply Agreement

IntelGenx Technologies Corp. announced that it has received $1.2 million in funding

First half earnings released

IntelGenx Technologies Corp. to Report Q2, 2020 Results on Aug 13, 2020

Analisi delle retribuzioni degli amministratori delegati

AMMINISTRATORE DELEGATO

Mandato